Last reviewed · How we verify

NCT06282445

Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer

Recruiting now Phase 2 Last updated 17 February 2025
What this trial tests

Phase 2 trial testing Adebrelimab in Colorectal Cancer Metastatic in 36 participants. Currently enrolling.

Timeline
1 March 2024
Primary endpoint
1 March 2025
31 March 2026

Quick facts

Lead sponsorThe Fourth Affiliated Hospital of Zhejiang University School of Medicine
PhasePhase 2
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment36
Start date1 March 2024
Primary completion1 March 2025
Estimated completion31 March 2026
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

The Fourth Affiliated Hospital of Zhejiang University School of Medicine

Who can join

Adults 18 to 75, any sex, with Colorectal Cancer Metastatic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the efficacy and safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Current and emerging concepts for systemic treatment of metastatic colorectal cancer.
    Steup C, Kennel KB, Neurath MF, Fichtner-Feigl S, et al · · 2025 · cited 10× · PMID 41047178 · DOI 10.1136/gutjnl-2025-335412

Verify or expand the search:

Other trials of Adebrelimab

Trials testing the same drug.

Other recruiting trials for Colorectal Cancer Metastatic

Currently open trials in the same condition.

Other The Fourth Affiliated Hospital of Zhejiang University School of Medicine trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06282445.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing